Novartis
1D
1W
1M
3M
1Y
5Y
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.About NVS
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate.
CEOVasant Narasimhan
CEOVasant Narasimhan
Employees104,323
Employees104,323
HeadquartersBasel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded1996
Founded1996
Employees104,323
Employees104,323
NVS Key Statistics
Market cap185.19B
Market cap185.19B
Price-Earnings ratio7.25
Price-Earnings ratio7.25
Dividend yield2.90
Dividend yield2.90
Average volume2.34M
Average volume2.34M
High today$76.62
High today$76.62
Low today$75.37
Low today$75.37
Open price$75.54
Open price$75.54
Volume3.65M
Volume3.65M
52 Week high$94.26
52 Week high$94.26
52 Week low$74.09
52 Week low$74.09
NVS News
Benzinga 22h
European Drug Makers Say Higher Energy Costs Eating Margins: Reportby Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby...
MarketWatch 5d
Novartis outlines plan to become a 'top-five player' in U.S. pharmaceuticals marketNovartis AG NOVN, -0.89% on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in...
Benzinga 6d
Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster BrandsNovartis AG (NYSE: NVS) has revealed insights into the updated company strategy. The company said that a 'US-first' mindset, increasing the share of U.S. patien...
Analyst ratings
50%
of 26 ratingsBuy
38.5%
Hold
50%
Sell
11.5%
NVS Earnings
$0.00
$0.57
$1.14
$1.71
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated— per share
Estimated— per share
ActualAvailable Oct 25, Pre-Market
ActualAvailable Oct 25, Pre-Market
More NVS News
Reuters 6d
Novartis to take U.S. drug patent case to Supreme Court - ReutersZURICH, Sept 21 (Reuters) - Novartis AG (NOVN.S) plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing reg...
